AHMED NADIM 4

What Happened
Ahmed Nadim, President, CEO and a director of Cullinan Therapeutics (CGEM), was granted 828,000 derivative shares on 2026-02-18. The Form 4 reports a $0.00 price and a total reported value of $0, indicating this was an equity award/option grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-19 (timely filing).
• Transaction type: Grant / award of derivative securities (code A).
• Amount: 828,000 shares (derivative/option). Price reported: $0.00; reported value: $0.
• Vesting: Footnote F1 — underlying shares vest over four years, with 1/48th vesting in equal monthly installments through the fourth anniversary.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed the next day; not indicated as late.

Context
This was an equity award (derivative/option grant) to the CEO, not a market purchase or sale. The grant vests monthly over four years, so the shares/options are earned over time rather than delivered immediately. Such grants are commonly used for executive compensation and retention; they do not by themselves indicate immediate buying or selling of stock.